79 related articles for article (PubMed ID: 23228387)
1. Autoimmune disease and subsequent urological cancer.
Liu X; Ji J; Forsti A; Sundquist K; Sundquist J; Hemminki K
J Urol; 2013 Jun; 189(6):2262-8. PubMed ID: 23228387
[TBL] [Abstract][Full Text] [Related]
2. Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
Jiang R; Wang X; Li Z; Cai H; Sun Z; Wu S; Chen S; Hu H
BMC Urol; 2023 Sep; 23(1):150. PubMed ID: 37736725
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibition and three urological cancers: Up-to-date results.
Lin L; Ning K; Xiang L; Peng L; Li X
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3797. PubMed ID: 38523292
[TBL] [Abstract][Full Text] [Related]
4. Twenty-two-year incidence trend of urological cancers in the Republic of Korea: 1999-2020.
Cho S; Park WJ
Investig Clin Urol; 2024 Jan; 65(1):23-31. PubMed ID: 38197748
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.
Corcoran AT; Smaldone MC; Egleston BL; Simhan J; Ginzburg S; Morgan TM; Walton J; Chen DY; Viterbo R; Greenberg RE; Uzzo RG; Kutikov A
BJU Int; 2013 Jul; 112(2):161-8. PubMed ID: 23795784
[TBL] [Abstract][Full Text] [Related]
6. Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
Chen LC; Yang HJ; Yu BH; Lee MS; Lin HY; Chiou WY; Liu DW; Hsu FC; Chew CH; Hung SK
PLoS One; 2024; 19(3):e0300391. PubMed ID: 38536840
[TBL] [Abstract][Full Text] [Related]
7. Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
Shen C; Zhang DL; Cheng XL; Zhang WC; Zhao JJ
Urol Int; 2023; 107(9):841-847. PubMed ID: 37769625
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Chronic Kidney Disease on the Mortality Rates of Patients with Urological Cancers-An Analysis of a Uro-Oncology Database from Eastern Europe.
Ciorcan M; Negru Ș; Bardan R; Cumpănaș A; Mattar I; Bitar Y; Chișavu L; Marc L; Schiller A; Mihăescu A
J Pers Med; 2023 Nov; 13(11):. PubMed ID: 38003887
[TBL] [Abstract][Full Text] [Related]
9. [Urological Cancer Current Status and Challenges of Liquid Biopsy in Urologic Tumors].
Nishiyama H
Gan To Kagaku Ryoho; 2024 Jan; 51(1):24. PubMed ID: 38247086
[No Abstract] [Full Text] [Related]
10. Comment on "Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project".
Kirchner JO
Drug Saf; 2023 Aug; 46(8):809-811. PubMed ID: 37243965
[No Abstract] [Full Text] [Related]
11. Height and kidney cancer risk: a meta-analysis of prospective studies.
Liang S; Lv G; Chen W; Jiang J; Wang J
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1799-807. PubMed ID: 25388591
[TBL] [Abstract][Full Text] [Related]
12. Parity and kidney cancer risk: evidence from epidemiologic studies.
Guan HB; Wu QJ; Gong TT
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2345-53. PubMed ID: 24108791
[TBL] [Abstract][Full Text] [Related]
13. Renal cancer in von Hippel-Lindau disease and related syndromes.
Bausch B; Jilg C; Gläsker S; Vortmeyer A; Lützen N; Anton A; Eng C; Neumann HP
Nat Rev Nephrol; 2013 Sep; 9(9):529-38. PubMed ID: 23897319
[TBL] [Abstract][Full Text] [Related]
14. Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies.
Choueiri TK; Je Y; Cho E
Int J Cancer; 2014 Jan; 134(2):384-96. PubMed ID: 23400756
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature.
Sabaté-Ortega J; Bujons-Buscarons E; Fina-Planas C; Vilanova-Anducas N; Vidal-Sarró N; Sala-González N
Front Oncol; 2023; 13():1223627. PubMed ID: 38023222
[TBL] [Abstract][Full Text] [Related]
16. The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel-A Retrospective Electronic Data-Based Study.
Kagan P; Horesh N; Amital H; Tsur AM; Watad A; Cohen AD; Ben-Shabat N
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568555
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis.
Ou J; Zhen K; Wu Y; Xue Z; Fang Y; Zhang Q; Bi H; Tian X; Ma L; Liu C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9517-9528. PubMed ID: 37213031
[TBL] [Abstract][Full Text] [Related]
18. Association between multiple sclerosis and prostate cancer risk: A systematic review and meta‑analysis.
Hu Z; Fu Y; Wang J; Li Y; Jiang Q
Oncol Lett; 2023 Feb; 25(2):83. PubMed ID: 36760514
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer.
Deichaite I; Sears TJ; Sutton L; Rebibo D; Morgan K; Nelson T; Rose B; Tamayo P; Ferrara N; Asimakopoulos F; Carter H
J Transl Med; 2022 Nov; 20(1):527. PubMed ID: 36371231
[TBL] [Abstract][Full Text] [Related]
20. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China.
Zhou Z; Liu H; Yang Y; Zhou J; Zhao L; Chen H; Fei Y; Zhang W; Li M; Zhao Y; Zeng X; Zhang F; Yang H; Zhang X
Cancer Commun (Lond); 2022 May; 42(5):435-446. PubMed ID: 35357093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
